Mohamed Ismail Nounou

Mohamed Ismail Nounou

Auto-generated profile, based on publicly available information

Mohamed Ismail Nounou

Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Breast Cancer: Basic and Clinical Research
Verified
Journal Article
Open access
MNMohamed I. Nounou
Mohamed I. Nounou
FEFatema ElAmrawy
Fatema ElAmrawy
NANada Ahmed
Nada Ahmed
KAKamilia Abdelraouf
Kamilia Abdelraouf
SGSatyanarayana Goda
Satyanarayana Goda
HSHussaini Syed-Sha-Qhattal
Hussaini Syed-Sha-Qhattal
Breast cancer is the most prevalent cancer among women worldwide. However, increased survival is due to the dramatic advances in the screening methods, early diagnosis, and breakthroughs in treatments. Over the course of the last decade, many acquisitions have taken place in this critical field of research in the pharmaceutical industry. Advances in molecular biology and pharmacology aided in better understanding of breast cancer, enabling the design of smarter therapeutics able to target cancer and respond to its microenvironment efficiently. Patents and research papers investigating diagnosis and treatment strategies for breast cancer using novel technologies have been surveyed for the past 15 years. Various nanocarriers have been introduced to improve the therapeutic efficacy of anticancer drugs, including liposomes, polymeric micelles, quantum dots, nanoparticles, and dendrimers. This review provides an overview of breast cancer, conventional therapy, novel technologies in the management of breast cancer, and rational approaches for targeting breast cancer. Highlights: Breast cancer is the most common cancer in women worldwide. However, survival rates vary widely, optimistically heading toward a positive trend. Increased survival is due to the drastic shift in the screening methods, early diagnosis, and breakthroughs in treatments. Different strategies of breast cancer classification and staging have evolved over the years. Intrinsic (molecular) subtyping is essential in clinical trials and well understanding of the disease. Many novel technologies are being developed to detect distant metastases and recurrent disease as well as to assess response to breast cancer management. Intensive research efforts are actively ongoing to take novel breast cancer therapeutics to potential clinical application. Most of the recent research papers and patents discuss one of the following strategies: the development of new drug entities that specifically target the breast tumor cells; tailor designing a novel carrier system that can multitask and multifunction as a drug carrier, targeting vehicle and even as a diagnostic tool, direct conjugation of a therapeutic drug moiety with a targeting moiety, diagnostic moiety or pharmacokinetics altering moiety; or the use of innovative nontraditional approaches such as genetic engineering, stem cells, or vaccinations.

1 January 2015 in Healthcare Informatics Research
Verified
Journal Article
Open access
PDF file
FEFatema El-Amrawy
Fatema El-Amrawy
MNMohamed Ismail Nounou
Mohamed Ismail Nounou
El-Amrawy F, et al. Healthc Inform Res. 2015 Oct;21(4):315-320. http://dx.doi.org/10.4258/hir.2015.21.4.315

29 August 2019 in Recent Advances in Drug Delivery and Formulation
Verified
Journal Article
Open access
PDF file
NHNada A. Helal
Nada A. Helal
HEHeba Eassa
Heba Eassa
AAAhmed M. Amer
Ahmed M. Amer
MEMohamed A. Eltokhy
Mohamed A. Eltokhy
IEIvan Edafiogho
Ivan Edafiogho
MNMohamed I. Nounou
Mohamed I. Nounou
: Traditional nutraceuticals and cosmeceuticals hold pragmatic nature with respect to their definitions, claims, purposes and marketing strategies. Their definitions are not well established worldwide. They also have different regulatory definitions and registration regulatory processes in different parts of the world. Global prevalence of nutraceuticals and cosmeceuticals is noticeably high with large market share with minimal regulation compared to traditional drugs. The global market is flooded with nutraceuticals and cosmeceuticals claiming to be of natural origin and sold with a therapeutic claim by major online retail stores such as Amazon and eBay. Apart from the traditional formulations, many manufacturers and researchers use novel formulation technologies in nutraceutical and cosmeceutical formulations for different reasons and objectives. Manufacturers tend to differentiate their products with novel formulations to increase market appeal and sales. On the other hand, researchers use novel strategies to enhance nutraceuticals and cosmeceuticals activity and safety. : The objective of this review is to assess the current patents and research adopting novel formulation strategies in nutraceuticals and cosmeceuticals. Patents and research papers investigating nutraceutical and cosmeceutical novel formulations were surveyed for the past 15 years. Various nanosystems and advanced biotechnology systems have been introduced to improve the therapeutic efficacy, safety and market appeal of nutraceuticals and cosmeceuticals, including liposomes, polymeric micelles, quantum dots, nanoparticles, and dendrimers. This review provides an overview of nutraceuticals and cosmeceuticals current technologies, highlighting their pros, cons, misconceptions, regulatory definitions and market. This review also aims in separating the science from fiction in the nutraceuticals and cosmeceuticals development, research and marketing.

1 August 2009 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
VMVicky V. Mody
Vicky V. Mody
MNMohamed Ismail Nounou
Mohamed Ismail Nounou
MBMalavosklish Bikram
Malavosklish Bikram

3 September 2013 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
RMRajendar K. Mittapalli
Rajendar K. Mittapalli
XLXinli Liu
Xinli Liu
CAChris E. Adkins
Chris E. Adkins
MNMohamed I. Nounou
Mohamed I. Nounou
KBKaci A. Bohn
Kaci A. Bohn
Paul LockmanPaul Lockman
Paul Lockman
Brain (central nervous system; CNS) metastases pose a life-threatening problem for women with advanced metastatic breast cancer. It has recently been shown that the vasculature within preclinical brain metastasis model markedly restricts paclitaxel delivery in approximately 90% of CNS lesions. Therefore to improve efficacy, we have developed an ultra-small hyaluronic acid (HA) paclitaxel nanoconjugate (∼5 kDa) that can passively diffuse across the leaky blood–tumor barrier and then be taken up into cancer cells (MDA–MB–231Br) via CD44 receptor–mediated endocytocis. Using CD44 receptor–mediated endocytosis as an uptake mechanism, HA-paclitaxel was able to bypass p-glycoprotein–mediated efflux on the surface of the cancer cells. In vitro cytoxicity of the conjugate and free paclitaxel were similar in that they (i) both caused cell-cycle arrest in the G2–M phase, (ii) showed similar degrees of apoptosis induction (cleaved caspase), and (iii) had similar IC50 values when compared with paclitaxel in MTT assay. A preclinical model of brain metastases of breast cancer using intracardiac injections of Luc-2 transfected MDA–MB–231Br cells was used to evaluate in vivo efficacy of the nanoconjugate. The animals administered with HA–paclitaxel nanoconjugate had significantly longer overall survival compared with the control and the paclitaxel-treated group (P < 0.05). This study suggests that the small molecular weight HA–paclitaxel nanoconjugates can improve standard chemotherapeutic drug efficacy in a preclinical model of brain metastases of breast cancer. Mol Cancer Ther; 12(11); 2389–99. ©2013 AACR.

26 July 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
TTTori B. Terrell-Hall
Tori B. Terrell-Hall
MNMohamed Ismail Nounou
Mohamed Ismail Nounou
FEFatema El-Amrawy
Fatema El-Amrawy
JGJessica Griffith
Jessica Griffith
Paul LockmanPaul Lockman
Paul Lockman
Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer